Matt Ruderman - Definitive Healthcare Chief Secretary
| DH Stock | USD 1.56 0.03 1.89% |
Executive
Matt Ruderman is Chief Secretary of Definitive Healthcare Corp
| Address | 492 Old Connecticut Path, Framingham, MA, United States, 01701 |
| Phone | 508 720 4224 |
| Web | https://www.definitivehc.com |
Definitive Healthcare Management Efficiency
The Definitive Healthcare's current Return On Tangible Assets is estimated to increase to -1.13. The Definitive Healthcare's current Return On Capital Employed is estimated to increase to -0.84. As of now, Definitive Healthcare's Intangibles To Total Assets are decreasing as compared to previous years. The Definitive Healthcare's current Fixed Asset Turnover is estimated to increase to 29.06, while Net Tangible Assets are projected to decrease to (682 M). Definitive Healthcare's management efficiency ratios could be used to measure how well Definitive Healthcare manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andy Monnich | National Research Corp | 49 | |
| Cara Bauer | Kyverna Therapeutics Common | N/A | |
| Wes Cronkite | TruBridge | 42 | |
| Mayo Pujols | Kyverna Therapeutics Common | 56 | |
| Michael CPA | Spok Holdings | 57 | |
| James MD | Kyverna Therapeutics Common | 56 | |
| Charlene JD | Editas Medicine | N/A | |
| SPHR CCP | Cabaletta Bio | 55 | |
| John MS | Simulations Plus | 46 | |
| Michael Daughton | TruBridge | N/A | |
| Timothy Tindle | Spok Holdings | 51 | |
| Frank Panaccio | Editas Medicine | N/A | |
| George Cardoza | Sophia Genetics SA | 63 | |
| Renee Hall | Spok Holdings | N/A | |
| Tracy Rossin | Kyverna Therapeutics Common | 50 | |
| Zhenyu Xu | Sophia Genetics SA | 43 | |
| Shawn OConnor | Simulations Plus | 66 | |
| Gregory Whitehead | Editas Medicine | N/A | |
| Grant Fowler | Simulations Plus | N/A | |
| Megan Charko | National Research Corp | N/A | |
| Jared MBA | Kindly MD | 44 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.0087 |
Definitive Healthcare Leadership Team
Elected by the shareholders, the Definitive Healthcare's board of directors comprises two types of representatives: Definitive Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Definitive. The board's role is to monitor Definitive Healthcare's management team and ensure that shareholders' interests are well served. Definitive Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Definitive Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, Chief Secretary | ||
| Jon Maack, President | ||
| Mary Delano, Senior Sciences | ||
| Justin Hubbard, SVP Business | ||
| Tina Hannagan, Chief Officer | ||
| Matt Ruderman, Chief Secretary | ||
| David Kronfeld, Chief Officer | ||
| Richard CPA, Chief Officer | ||
| Marissa Odell, Senior Diversified | ||
| Rebecca Marani, Senior Provider | ||
| Justin Steinman, Chief Officer | ||
| Craig Hazenfield, Chief Officer | ||
| Jeannine Lombardi, Chief Officer | ||
| Scott Oberlink, Chief Officer | ||
| Kevin Coop, CEO Director | ||
| Casey Heller, Senior Finance | ||
| Kate Hastings, Chief Officer | ||
| Benjamin Graboske, Technology, EVP | ||
| Kate Jensen, Chief Officer | ||
| Carrie Lazorchak, Chief Officer | ||
| Tom Penque, Chief Officer | ||
| Sally Slarke, Senior Excellence | ||
| Jonathan Maack, President | ||
| Michelle Liro, Senior Marketing | ||
| Ram Sharma, Executive Sciences | ||
| Jeannine Sheehan, Chief Officer | ||
| Jason Krantz, Executive Founder | ||
| William Moschella, Chief Officer | ||
| Robert JD, CEO Director | ||
| Richard Booth, Chief Officer | ||
| Matthew Ruderman, Chief Secretary | ||
| Joseph Mirisola, Chief Officer |
Definitive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Definitive Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.0087 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 153.73 M | ||||
| Shares Outstanding | 103.3 M | ||||
| Shares Owned By Insiders | 8.84 % | ||||
| Shares Owned By Institutions | 90.46 % | ||||
| Number Of Shares Shorted | 2.42 M | ||||
| Price To Book | 0.58 X |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Definitive Healthcare Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is there potential for Health Care Technology market expansion? Will Definitive introduce new products? Factors like these will boost the valuation of Definitive Healthcare. Projected growth potential of Definitive fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Definitive Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.72) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of Definitive Healthcare is measured differently than its book value, which is the value of Definitive that is recorded on the company's balance sheet. Investors also form their own opinion of Definitive Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Definitive Healthcare's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Definitive Healthcare's market value can be influenced by many factors that don't directly affect Definitive Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Definitive Healthcare's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Definitive Healthcare should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Definitive Healthcare's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.